Janux Therapeutics (JANX)
(Real Time Quote from BATS)
$47.81 USD
-2.18 (-4.36%)
Updated May 14, 2024 03:30 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Janux Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -58.29 | -63.06 | -32.67 | -6.78 | -4.00 |
Depreciation/Amortization & Depletion | -5.73 | -1.34 | -0.06 | 0.01 | 0.01 |
Net Change from Assets/Liabilities | -6.55 | 4.28 | 8.84 | 0.39 | -0.07 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 20.01 | 17.20 | 6.91 | 2.01 | 0.24 |
Net Cash From Operating Activities | -50.58 | -42.92 | -16.98 | -4.37 | -3.83 |
Property & Equipment | -1.85 | -6.45 | -1.48 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -39.34 | 64.71 | -339.48 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -41.19 | 58.27 | -340.96 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 59.55 | 0.50 | 182.36 | 9.02 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 2.50 | 4.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 204.17 | 0.00 | 0.00 |
Net Cash from Financing Activities | 59.55 | 0.50 | 386.52 | 11.52 | 4.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -32.22 | 15.84 | 28.59 | 7.16 | 0.17 |
Cash at Beginning of Period | 52.24 | 36.40 | 7.81 | 0.66 | 0.49 |
Cash at End of Period | 20.02 | 52.24 | 36.40 | 7.81 | 0.66 |
Diluted Net EPS | -1.32 | -1.52 | -1.39 | -7.41 | NA |
Fiscal Year End for Janux Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -14.76 | -58.29 | -46.54 | -34.97 | -17.46 |
Depreciation/Amortization & Depletion | -1.26 | -5.73 | -4.20 | -2.60 | -1.23 |
Net Change from Assets/Liabilities | -4.45 | -6.55 | -5.46 | -2.38 | -0.70 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.63 | 20.01 | 15.52 | 10.97 | 5.47 |
Net Cash From Operating Activities | -14.84 | -50.58 | -40.67 | -28.97 | -13.91 |
Property & Equipment | -0.20 | -1.85 | -1.34 | -0.87 | -0.29 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -113.54 | -39.34 | -50.98 | 10.00 | -8.46 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -113.74 | -41.19 | -52.32 | 9.13 | -8.74 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 322.17 | 59.55 | 58.72 | 2.11 | 1.58 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 322.17 | 59.55 | 58.72 | 2.11 | 1.58 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 193.60 | -32.22 | -34.27 | -17.72 | -21.07 |
Cash at Beginning of Period | 20.02 | 52.24 | 52.24 | 52.24 | 52.24 |
Cash at End of Period | 213.62 | 20.02 | 17.97 | 34.52 | 31.17 |
Diluted Net EPS | -0.30 | -0.23 | -0.25 | -0.42 | -0.42 |